Revenue and profit grew in H1 2026, led by Biopharma and strong IG demand, with adjusted EBITDA and free cash flow improving year-over-year. Albumin in China is stabilizing, diagnostics is advancing post-JV, and plasma sourcing in Egypt is ramping up, supporting 2026 guidance.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.